cancer regression patients transfer genetically engineered lymphocytes
adoptive transfer lymphocytes host immunodepletion possible mediate objective cancer regression human patients metastatic melanoma however generation tumor-specific t cells mode immunotherapy often limiting report ability specifically confer tumor recognition autologous lymphocytes peripheral blood using retrovirus encodes t cell receptor adoptive transfer transduced cells patients resulted durable engraftment levels exceeding % peripheral blood lymphocytes least months infusion observed high sustained levels circulating engineered cells year infusion two patients demonstrated objective regression metastatic melanoma lesions study suggests therapeutic potential genetically engineered cells biologic therapy cancer
